PDF(Pubmed)
Abstract：
UNASSIGNED: Early diagnosis of esophageal squamous cell carcinoma (ESCC) is critical for effective treatment and optimal prognosis; however, less study on serum biomarkers for the early ESCC detection has been reported. The aim of this study was to identify and evaluate several serum autoantibody biomarkers in early ESCC.
UNASSIGNED: We initially screened candidate tumor-associated autoantibodies (TAAbs) associated with ESCC by serological proteome analysis (SERPA) combined with nanoliter-liquid chromatography combined with quadrupole time of flight tandem mass spectrometry (nano-LC-Q-TOF-MS/MS), and the TAAbs were further subjected to analysis by Enzyme-linked immunosorbent assay (ELISA) in a clinical cohort (386 participants, including 161 patients with ESCC, 49 patients with high-grade intraepithelial neoplasia [HGIN] and 176 healthy controls [HC]). Receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic performance.
UNASSIGNED: The serum levels of CETN2 and POFUT1 autoantibodies which were identified by SERPA were statistically different between ESCC or HGIN patients and HC in ELISA analysis with the area under the curve (AUC) values of 0.709 (95%CI: 0.654-0.764) and 0.741 (95%CI: 0.689-0.793), 0.717 (95%CI: 0.634-0.800) and 0.703 (95%CI: 0.627-0.779) for detection of ESCC and HGIN, respectively. Combining these two markers, the AUCs were 0.781 (95%CI: 0.733-0.829), 0.754 (95%CI: 0.694-0.814) and 0.756 (95%CI: 0.686-0.827) when distinguishing ESCC, early ESCC and HGIN from HC, respectively. Meanwhile, the expression of CETN2 and POFUT1 was found to be correlated with ESCC progression.
UNASSIGNED: Our data suggest that CETN2 and POFUT1 autoantibodies have potential diagnostic value for ESCC and HGIN, which may provide novel insights for early ESCC and precancerous lesions detection.
UNASSIGNED: We initially screened candidate tumor-associated autoantibodies (TAAbs) associated with ESCC by serological proteome analysis (SERPA) combined with nanoliter-liquid chromatography combined with quadrupole time of flight tandem mass spectrometry (nano-LC-Q-TOF-MS/MS), and the TAAbs were further subjected to analysis by Enzyme-linked immunosorbent assay (ELISA) in a clinical cohort (386 participants, including 161 patients with ESCC, 49 patients with high-grade intraepithelial neoplasia [HGIN] and 176 healthy controls [HC]). Receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic performance.
UNASSIGNED: The serum levels of CETN2 and POFUT1 autoantibodies which were identified by SERPA were statistically different between ESCC or HGIN patients and HC in ELISA analysis with the area under the curve (AUC) values of 0.709 (95%CI: 0.654-0.764) and 0.741 (95%CI: 0.689-0.793), 0.717 (95%CI: 0.634-0.800) and 0.703 (95%CI: 0.627-0.779) for detection of ESCC and HGIN, respectively. Combining these two markers, the AUCs were 0.781 (95%CI: 0.733-0.829), 0.754 (95%CI: 0.694-0.814) and 0.756 (95%CI: 0.686-0.827) when distinguishing ESCC, early ESCC and HGIN from HC, respectively. Meanwhile, the expression of CETN2 and POFUT1 was found to be correlated with ESCC progression.
UNASSIGNED: Our data suggest that CETN2 and POFUT1 autoantibodies have potential diagnostic value for ESCC and HGIN, which may provide novel insights for early ESCC and precancerous lesions detection.
摘要：
■食管鳞状细胞癌（ESCC）的早期诊断对于有效治疗和最佳预后至关重要；然而，关于早期ESCC检测的血清生物标志物的研究较少。这项研究的目的是鉴定和评估早期ESCC中的几种血清自身抗体生物标志物。
■我们最初通过血清学蛋白质组分析（SERPA）结合纳升液相色谱结合四极杆飞行时间串联质谱（nano-LC-Q-TOF-MS/MS）筛选了与ESCC相关的候选肿瘤相关自身抗体（TAAbs），并在临床队列中通过酶联免疫吸附测定（ELISA）进一步对TAAbs进行分析（386名参与者，包括161名ESCC患者，49例高级别上皮内瘤变[HGIN]和176例健康对照[HC])。绘制受试者工作特征（ROC）曲线以评估诊断性能。
■在ELISA分析中，通过SERPA鉴定的ESCC或HGIN患者与HC之间的CETN2和POFUT1自身抗体的血清水平具有统计学差异，曲线下面积（AUC）值为0.709（95CI：0.654-0.764）和0.741（95CI：0.689-0.793），0.717（95CI：0.634-0.800）和0.703（95CI：0.627-0.779）用于检测ESCC和HGIN，分别。结合这两个标记，AUC为0.781（95CI：0.733-0.829），0.754（95CI：0.694-0.814）和0.756（95CI：0.686-0.827）在区分ESCC时，早期ESCC和HC的HGIN，分别。同时,发现CETN2和POFUT1的表达与ESCC进展相关。
■我们的数据表明，CETN2和POFUT1自身抗体对ESCC和HGIN具有潜在的诊断价值，这可能为早期ESCC和癌前病变检测提供新的见解。
■我们最初通过血清学蛋白质组分析（SERPA）结合纳升液相色谱结合四极杆飞行时间串联质谱（nano-LC-Q-TOF-MS/MS）筛选了与ESCC相关的候选肿瘤相关自身抗体（TAAbs），并在临床队列中通过酶联免疫吸附测定（ELISA）进一步对TAAbs进行分析（386名参与者，包括161名ESCC患者，49例高级别上皮内瘤变[HGIN]和176例健康对照[HC])。绘制受试者工作特征（ROC）曲线以评估诊断性能。
■在ELISA分析中，通过SERPA鉴定的ESCC或HGIN患者与HC之间的CETN2和POFUT1自身抗体的血清水平具有统计学差异，曲线下面积（AUC）值为0.709（95CI：0.654-0.764）和0.741（95CI：0.689-0.793），0.717（95CI：0.634-0.800）和0.703（95CI：0.627-0.779）用于检测ESCC和HGIN，分别。结合这两个标记，AUC为0.781（95CI：0.733-0.829），0.754（95CI：0.694-0.814）和0.756（95CI：0.686-0.827）在区分ESCC时，早期ESCC和HC的HGIN，分别。同时,发现CETN2和POFUT1的表达与ESCC进展相关。
■我们的数据表明，CETN2和POFUT1自身抗体对ESCC和HGIN具有潜在的诊断价值，这可能为早期ESCC和癌前病变检测提供新的见解。
